buserelin has been researched along with acid phosphatase in 27 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 20 (74.07) | 18.7374 |
| 1990's | 7 (25.93) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Debruyne, FM; Fernandez del Moral, P; Mulders, PF; Oosterhof, GO; Theeuwes, AG; van Berkel, HT | 1 |
| Dundas, GS; Porter, AT; Venner, PM | 1 |
| Block, NL; Chodak, G; Gau, TC; Kennealey, G; Schellhammer, PF; Scott, M; Smith, JA; Soloway, MS; Vogelzang, NJ | 1 |
| Ansari, AS; Jayaprakash, D; Kumar, M; Lohiya, NK; Sharma, K; Sharma, S | 1 |
| Schulze, H; Senge, T | 1 |
| D'Eramo, G; Di Silverio, F; Sciarra, F; Serio, M | 1 |
| Cooper, EH; Denis, L; Hetherington, JW; Newling, DW; Richards, B; Robinson, MR; Siddall, JK | 1 |
| Blackledge, GR; Emtage, LA; Lewis, PW | 1 |
| Ayalon, D; Braf, Z; Lewyshon, O; Matzkin, H | 1 |
| Braf, Z; Greenstein, A; Kaver, I; Matzkin, H | 1 |
| Billebaud, T; Costa, P; Dahan, R; Fiet, J; Grise, P; Husson, JM; Kuhn, JM; Louis, JF; Moulonguet, A; Navratil, H | 1 |
| Beacock, CJ; Buck, AC; Griffiths, K; Peeling, WB; Rees, RW; Turkes, A; Walker, K; Zwinck, R | 1 |
| Adenis, L; Audhuy, B; Bugat, R; Colombel, P; Couette, JE; Grise, P; Khater, R; LePorz, B; Metz, R; Namer, M | 1 |
| Huhtaniemi, I; Nikula, H; Rannikko, S | 1 |
| Clayton, R; Huhtaniemi, I; Nikula, H; Rannikko, S | 1 |
| Debruyne, FM; Fernandez del Moral, P; Litjens, TT; van Laarhoven, JP; Weil, EH | 1 |
| Navratil, H | 1 |
| de Jong, FH; de Voogt, HJ; Debruyne, FM; Karthaus, HF; Klijn, JG; Schröder, FH | 1 |
| Koutsilieris, M; Tolis, G | 2 |
| Allen, J; Bloom, SR; Doble, A; Kerle, D; Ware, H; Williams, G | 1 |
| Belanger, A; Dupont, A; Fazekas, AT; Gareau, J; Husson, JM; Labrie, F; Lacoursiere, Y; Monfette, G; Raynaud, JP; Sandow, J | 1 |
| Faure, N; Fazekas, AT; Jean, C; Laroche, B; Lemay, A; Plante, R; Robert, G; Roy, R; Thabet, M | 1 |
| Belanger, A; Dupont, A; Labrie, F; Lefebvre, FA; Raynaud, JP | 1 |
| Bélanger, A; Dupont, A; Emond, J; Labrie, F; Monfette, G | 1 |
| Dufresne, M; Herrera, R; Koutsilieris, M; Martinez, A; Stellos, A; Tolis, G | 1 |
| de Pauw, M; de Voogt, HJ; Klijn, JG; Schröder, FH; Studer, U; Sylvester, R | 1 |
1 review(s) available for buserelin and acid phosphatase
| Article | Year |
|---|---|
[New approach in the treatment of prostatic cancer: combined use of a LHRH agonist and an androgen antagonist].
Topics: Acid Phosphatase; Androgen Antagonists; Buserelin; Drug Synergism; Drug Therapy, Combination; Gonadotropin-Releasing Hormone; Hormones; Humans; Imidazoles; Imidazolidines; Male; Prostate; Prostatic Neoplasms | 1983 |
9 trial(s) available for buserelin and acid phosphatase
| Article | Year |
|---|---|
Zoladex versus orchiectomy in treatment of advanced prostate cancer: a randomized trial. Zoladex Prostate Study Group.
Topics: Acid Phosphatase; Adenocarcinoma; Aged; Aged, 80 and over; Buserelin; Follow-Up Studies; Goserelin; Humans; Male; Middle Aged; Neoplasm Staging; Orchiectomy; Prospective Studies; Prostatic Neoplasms; Testosterone | 1991 |
Zoladex vs. Zoladex plus cyproterone acetate in the treatment of advanced prostatic cancer: a multicenter Italian study.
Topics: Acid Phosphatase; Aged; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Buserelin; Cyproterone; Cyproterone Acetate; Follow-Up Studies; Gonadotropin-Releasing Hormone; Goserelin; Humans; Male; Prostatic Neoplasms; Testosterone | 1990 |
The role of prostate specific antigen in the baseline assessment of patients undergoing hormone therapy for advanced prostate cancer.
Topics: Acid Phosphatase; Alkaline Phosphatase; Antigens, Neoplasm; Biomarkers, Tumor; Bone Neoplasms; Buserelin; Diethylstilbestrol; Goserelin; Humans; Male; Prostate; Prostate-Specific Antigen; Prostatic Neoplasms; Random Allocation | 1987 |
Prevention of the transient adverse effects of a gonadotropin-releasing hormone analogue (buserelin) in metastatic prostatic carcinoma by administration of an antiandrogen (nilutamide).
Topics: Acid Phosphatase; Aged; Androgen Antagonists; Buserelin; Drug Evaluation; Humans; Imidazoles; Imidazolidines; Male; Multicenter Studies as Topic; Neoplasm Metastasis; Prostatic Neoplasms; Testosterone | 1989 |
Zoladex as primary therapy in advanced prostatic cancer. A French cooperative trial.
Topics: Acid Phosphatase; Aged; Aged, 80 and over; Buserelin; Delayed-Action Preparations; Follicle Stimulating Hormone; France; Goserelin; Humans; Injections, Subcutaneous; Luteinizing Hormone; Male; Middle Aged; Multicenter Studies as Topic; Neoplasm Metastasis; Neoplasms, Hormone-Dependent; Prospective Studies; Prostate; Prostatic Neoplasms | 1988 |
Double-blind study of Anandron versus placebo in stage D2 prostate cancer patients receiving buserelin. Results on 49 cases from a multicentre study.
Topics: Acid Phosphatase; Aged; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Buserelin; Clinical Trials as Topic; Double-Blind Method; Humans; Imidazoles; Imidazolidines; Male; Prostatic Neoplasms | 1987 |
Long-term follow-up of patients with advanced prostatic carcinoma treated with either buserelin (HOE 766) or orchiectomy: classification of variables associated with disease outcome.
Topics: Acid Phosphatase; Bone and Bones; Buserelin; Estradiol; Flushing; Follow-Up Studies; Humans; Male; Orchiectomy; Prostatic Neoplasms; Radionuclide Imaging; Testosterone; Ultrasonics | 1985 |
Advanced prostatic adenocarcinoma: biological aspects and effects of androgen deprivation achieved by castration or agonistic analogues of LHRH.
Topics: Acid Phosphatase; Adenocarcinoma; Alkaline Phosphatase; Bone and Bones; Buserelin; Hormones; Humans; Male; Neoplasm Staging; Orchiectomy; Prostate; Prostatic Neoplasms; Radiography; Receptors, Androgen; Ultrasonography | 1984 |
Maximum androgen blockade using LHRH agonist buserelin in combination with short-term (two weeks) or long-term (continuous) cyproterone acetate is not superior to standard androgen deprivation in the treatment of advanced prostate cancer. Final analysis o
Topics: Acid Phosphatase; Administration, Intranasal; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Buserelin; Carcinoma; Cause of Death; Cyproterone Acetate; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Injections, Subcutaneous; Male; Middle Aged; Orchiectomy; Pain Measurement; Proportional Hazards Models; Prospective Studies; Prostatic Neoplasms; Survival Rate; Treatment Outcome | 1998 |
17 other study(ies) available for buserelin and acid phosphatase
| Article | Year |
|---|---|
Value of biochemical markers in the management of disseminated prostatic cancer.
Topics: Acid Phosphatase; Alkaline Phosphatase; Antigens, Neoplasm; Biomarkers, Tumor; Buserelin; Follow-Up Studies; Goserelin; Humans; Male; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms; Time Factors | 1992 |
Prostate-specific antigen. Monitoring the response of carcinoma of the prostate to radiotherapy with a new tumor marker.
Topics: Acid Phosphatase; Aged; Aged, 80 and over; Antigens, Neoplasm; Biomarkers, Tumor; Brachytherapy; Buserelin; Follow-Up Studies; Goserelin; Humans; Male; Middle Aged; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms | 1990 |
Experience with a potent LH-RH agonist, buserelin, alone and in combination with testosterone for antispermatogenic activity, reversibility and toxicity in langur monkey.
Topics: Acid Phosphatase; Animals; Antispermatogenic Agents; Body Weight; Buserelin; Drug Combinations; Drug Synergism; Fructose; Gonadotropin-Releasing Hormone; Haplorhini; L-Lactate Dehydrogenase; Libido; Magnesium; Male; Oligospermia; Sperm Count; Sperm Motility; Spermatogenesis; Testis; Testosterone | 1991 |
Influence of different types of antiandrogens on luteinizing hormone-releasing hormone analogue-induced testosterone surge in patients with metastatic carcinoma of the prostate.
Topics: Acid Phosphatase; Aged; Androgen Antagonists; Buserelin; Cyproterone; Cyproterone Acetate; Drug Therapy, Combination; Flutamide; Goserelin; Humans; Luteinizing Hormone; Male; Premedication; Prostatic Neoplasms; Testosterone; Time Factors | 1990 |
Biochemical monitoring of carcinoma of prostate treated with an LH-RH analogue (Zoladex).
Topics: Acid Phosphatase; Aged; Aged, 80 and over; alpha-2-HS-Glycoprotein; Antigens; Blood Proteins; Buserelin; Goserelin; Humans; Luteinizing Hormone; Male; Middle Aged; Orosomucoid; Prolactin; Prostate-Specific Antigen; Prostatic Neoplasms; Radioimmunoassay; Testosterone | 1986 |
Changes in prostate-specific markers under chronic gonadotrophin-releasing hormone analogue treatment of state D prostatic cancer.
Topics: Acid Phosphatase; Aged; Aged, 80 and over; Antigens, Neoplasm; Biomarkers, Tumor; Buserelin; Follow-Up Studies; Hormones; Humans; Male; Middle Aged; Neoplasm Staging; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms | 1989 |
Use of gonadotropin-releasing hormone analogue in advanced prostatic cancer: 3 years clinical experience.
Topics: Acid Phosphatase; Aged; Aged, 80 and over; Antigens, Neoplasm; Biomarkers, Tumor; Buserelin; Carcinoma; Clinical Enzyme Tests; Drug Evaluation; Follow-Up Studies; Humans; Male; Middle Aged; Prostate; Prostate-Specific Antigen; Prostatic Neoplasms; Time Factors | 1989 |
The treatment of metastatic prostatic cancer with the slow release LH-RH analogue Zoladex ICI 118630.
Topics: Acid Phosphatase; Aged; Alkaline Phosphatase; Bone Neoplasms; Buserelin; Delayed-Action Preparations; Goserelin; Humans; Luteinizing Hormone; Lymphatic Metastasis; Male; Middle Aged; Prospective Studies; Prostatic Neoplasms; Random Allocation; Testosterone | 1987 |
Treatment of prostatic cancer with a gonadotropin-releasing hormone agonist analog: acute and long term effects on endocrine functions of testis tissue.
Topics: Acid Phosphatase; Aged; Buserelin; Follicle Stimulating Hormone; Humans; In Vitro Techniques; Luteinizing Hormone; Male; Middle Aged; Prolactin; Prostatic Neoplasms; Receptors, Cell Surface; Receptors, FSH; Receptors, LH; Testis; Testosterone; Time Factors | 1985 |
Regulation of testicular steroidogenesis by gonadotropin-releasing hormone agonists and antagonists.
Topics: Acid Phosphatase; Aged; Animals; Buserelin; Follicle Stimulating Hormone; Humans; Luteinizing Hormone; Male; Middle Aged; Pituitary Hormone-Releasing Hormones; Prostatic Neoplasms; Rats; Receptors, Cell Surface; Receptors, FSH; Receptors, LH; Receptors, LHRH; Receptors, Prolactin; Testis; Testosterone | 1986 |
[Treatment of advanced prostate carcinoma with a depot form of an LH-RH analog: preliminary endocrinological and clinical results].
Topics: Acid Phosphatase; Aged; Buserelin; Delayed-Action Preparations; Drug Evaluation; Humans; Injections, Subcutaneous; Male; Middle Aged; Prostatic Neoplasms; Testosterone | 1986 |
Results of a Dutch Phase II trial with the LHRH agonist buserelin in patients with metastatic prostatic cancer.
Topics: Acid Phosphatase; Aged; Buserelin; Drug Evaluation; Follicle Stimulating Hormone; Gonadotropin-Releasing Hormone; Humans; Luteinizing Hormone; Male; Middle Aged; Neoplasm Metastasis; Prostatic Neoplasms; Testosterone | 1985 |
Experience with an LHRH analogue in the management of relapsed progressive prostatic cancer.
Topics: Acid Phosphatase; Alkaline Phosphatase; Analgesia; Bone Neoplasms; Buserelin; Goserelin; Hormones; Humans; Male; Prostatic Neoplasms | 1984 |
Gonadotropin-releasing hormone agonistic analogues in the treatment of advanced prostatic carcinoma.
Topics: Acid Phosphatase; Alkaline Phosphatase; Buserelin; Hormones; Humans; Male; Neoplasm Staging; Prostatic Neoplasms; Radiography; Testosterone | 1983 |
New approach in the treatment of prostate cancer: complete instead of partial withdrawal of androgens.
Topics: Acid Phosphatase; Aged; Androgen Antagonists; Buserelin; Drug Therapy, Combination; Hormones; Humans; Imidazoles; Imidazolidines; Male; Middle Aged; Prostatic Neoplasms; Radiography; Testosterone | 1983 |
Preliminary results on the clinical efficacy and safety of androgen inhibition by an LHRH agonist alone or combined with an antiandrogen in the treatment of prostatic carcinoma.
Topics: Acid Phosphatase; Aged; Androgen Antagonists; Bone and Bones; Buserelin; Castration; Drug Therapy, Combination; Hormones; Humans; Imidazoles; Imidazolidines; Luteinizing Hormone; Male; Middle Aged; Prostatic Neoplasms; Radiography; Testis; Testosterone | 1983 |
Simultaneous administration of pure antiandrogens, a combination necessary for the use of luteinizing hormone-releasing hormone agonists in the treatment of prostate cancer.
Topics: Acid Phosphatase; Adenocarcinoma; Androgen Antagonists; Buserelin; Drug Therapy, Combination; Humans; Imidazoles; Imidazolidines; Male; Prostatic Neoplasms; Testosterone | 1984 |